Actualités

Communiqué de Presse

Financial Press Release | Oncodesign
Communiqué de Presse
05/10/2017

Oncodesign launches its new website

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
31/08/2017

Oncodesign announces the acquisition of Bertin Pharma’s pharmaceutical and biotech services businesses

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
10/05/2017

Oncodesign opens exclusive negotiations with Bertin Pharma for the acquisition of service businesses

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
03/04/2017

Oncodesign presents its latest scientific developments at the AACR annual global meeting on oncology

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
30/03/2017

Business update and FY 2016 results

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
15/03/2017

Oncodesign announces return of research collaboration and option to license rights for Parkinson program from Ipsen

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
07/02/2017

Oncodesign’s OncoSNIPE® collaborative programme receives €7.7 million in support from the “Investments for the Future Programme” operated by Bpifrance

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
21/11/2016

ONCODESIGN wins the 4th European Small and Mid-Cap Awards in the “Rising Star” category 21/11/16 TELECHARGER

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
17/11/2016

2017-2020 strategic plan

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
28/09/2016

GSK and Oncodesign announce agreement for Oncodesign’s acquisition of GSK’s Research Centre in France

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
12/07/2016

Oncodesign announces the launch of its first clinical study on a radiotracer in patients with non-small cell lung cancer

Lire la suite
Financial Press Release | Oncodesign
Communiqué de Presse
30/05/2016

Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors

Lire la suite